Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Negative Gastric Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT04764084
What this trial is testing

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Who this might be right for
HER2-negative Breast CancerGastric AdenocarcinomaCholangiocarcinoma+1 more
Peking University Cancer Hospital & Institute 52
Large-scale testing (Phase 3)Not Yet RecruitingNCT07700979
What this trial is testing

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

Who this might be right for
Gastric / Gastroesophageal Junction Adenocarcinoma
Akeso 900
Early research (Phase 1)UnknownNCT04508686
What this trial is testing

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)

Who this might be right for
Advanced Cervical Cancer
Ruijin Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT04168931
What this trial is testing

Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC

Who this might be right for
Gastric Cancer Stage IV
AC Camargo Cancer Center 5
Testing effectiveness (Phase 2)Looking for participantsNCT06774222
What this trial is testing

Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG

Who this might be right for
Gastric/Gastroesophageal Junction Adenocarcinoma
Henan Cancer Hospital 69
Early research (Phase 1)Looking for participantsNCT06773312
What this trial is testing

BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Advanced or Metastatic Gastric CancerGastroesophageal Junction Adenocarcinoma
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. 80
Early research (Phase 1)Active Not RecruitingNCT06257264
What this trial is testing

Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Who this might be right for
Breast CancerSmall Cell Lung CancerOvarian Cancer+9 more
BeiGene 103
Early research (Phase 1)UnknownNCT04460456
What this trial is testing

SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Who this might be right for
HER2 Positive Solid Tumors
Silverback Therapeutics 58
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06748508
What this trial is testing

Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer

Who this might be right for
Gastric (Stomach) Cancer
Fudan University 141
Not applicableLooking for participantsNCT06277024
What this trial is testing

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Who this might be right for
Overall Response Rate
Fujian Medical University 50
Not applicableUnknownNCT06034964
What this trial is testing

Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC

Who this might be right for
TislelizumabChemotherapyFirst-line+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06992024
What this trial is testing

Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer

Who this might be right for
Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 25
Early research (Phase 1)Looking for participantsNCT07801508
What this trial is testing

[68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors

Who this might be right for
Advanced Gastroesophageal AdenocarcinomaAdvanced Breast CancerTriple-negative Breast Cancer+1 more
Novartis Pharmaceuticals 66
Testing effectiveness (Phase 2)Looking for participantsNCT07523529
What this trial is testing

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

Who this might be right for
Advanced UnresectableMetastatic
Beijing Biotech 72
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Early research (Phase 1)Ended earlyNCT05069935
What this trial is testing

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Who this might be right for
Solid Tumor, Adult
Fate Therapeutics 16
Post-approval studies (Phase 4)Not Yet RecruitingNCT07502027
What this trial is testing

A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer (Diagnosis)Gastric Cancer (GC)Gastroesophageal Junction Adenocarcinoma
Huazhong University of Science and Technology 55
Testing effectiveness (Phase 2)Ended earlyNCT04504916
What this trial is testing

Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Who this might be right for
Triple-negative Breast CancerNon-squamous Non-small-cell Lung CancerNSCLC+12 more
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 102
Post-approval studies (Phase 4)Not Yet RecruitingNCT07829757
What this trial is testing

Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Large-scale testing (Phase 3)Not Yet RecruitingNCT05914610
What this trial is testing

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Fujian Medical University 100
Next Page
50